Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

PLYMOUTH MEETING, Pa., Jan. 5, 2022 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.

• 40th Annual J.P. Morgan Healthcare ConferencePresentation: Thursday, January 13, 2022; 7:30AM ET1x1 Meetings: Monday, January 10, 2022-Thursday, January 13, 2022

A webcast of the presentation will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.

Harmony Biosciences Media Contact: Nancy Leone 215-891-6046 nleone@harmonybiosciences.com 

Harmony Biosciences Investor Contact:Patti BankICR Westwicke415-513-1284ir@harmonybiosciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-40th-annual-jp-morgan-healthcare-conference-301454023.html

SOURCE Harmony Biosciences